TD Asset Management
ACAD icon

TD Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

TD Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65,000
Closed -$1.39M – 1233
2025
Q3 		$1.39M Buy
65,000
+20,000
+44% +$473K ﹤0.01% 1036
2025
Q2 		$971K Buy
+45,000
New +$836K ﹤0.01% 1065
2024
Q3 		– Sell
-23,296
Closed -$379K – 1386
2024
Q2 		$379K Sell
23,296
-82,800
-78% -$1.34M ﹤0.01% 1305
2024
Q1 		$1.96M Sell
106,096
-100,400
-49% -$2.49M ﹤0.01% 1029
2023
Q4 		$6.47M Sell
206,496
-19,200
-9% -$459K 0.01% 697
2023
Q3 		$4.7M Buy
225,696
+51,273
+29% +$1.39M 0.01% 745
2023
Q2 		$4.18M Buy
174,423
+57,502
+49% +$1.28M ﹤0.01% 786
2023
Q1 		$2.2M Buy
116,921
+13,600
+13% +$259K ﹤0.01% 954
2022
Q4 		$1.64M Sell
103,321
-23,339
-18% -$365K ﹤0.01% 1042
2022
Q3 		$2.04M Buy
126,660
+15,300
+14% +$248K ﹤0.01% 991
2022
Q2 		$1.57M Buy
111,360
+15,400
+16% +$287K ﹤0.01% 1075
2022
Q1 		$2.32M Sell
95,960
-40,882
-30% -$989K ﹤0.01% 1043
2021
Q4 		$3.19M Buy
136,842
+11,791
+9% +$237K ﹤0.01% 1006
2021
Q3 		$2.08M Sell
125,051
-12,700
-9% -$245K ﹤0.01% 1073
2021
Q2 		$2.98M Sell
137,751
-1,766
-1% -$39.9K ﹤0.01% 964
2021
Q1 		$3.6M Sell
139,517
-43,656
-24% -$1.92M ﹤0.01% 924
2020
Q4 		$9.79M Sell
183,173
-59,200
-24% -$2.94M 0.01% 597
2020
Q3 		$10M Sell
242,373
-13,100
-5% -$566K 0.01% 547
2020
Q2 		$12.4M Buy
255,473
+10,297
+4% +$494K 0.02% 468
2020
Q1 		$10.4M Sell
245,176
-37,943
-13% -$1.56M 0.02% 463
2019
Q4 		$12.1M Buy
283,119
+75,214
+36% +$3.27M 0.02% 502
2019
Q3 		$7.48M Buy
207,905
+42,456
+26% +$1.29M 0.01% 592
2019
Q2 		$4.42M Buy
165,449
+5,700
+4% +$146K 0.01% 711
2019
Q1 		$4.29M Buy
159,749
+12,500
+8% +$292K 0.01% 732
2018
Q4 		$2.38M Buy
147,249
+39,649
+37% +$770K ﹤0.01% 871
2018
Q3 		$2.23M Buy
+107,600
New +$1.69M ﹤0.01% 964
2017
Q4 		– Sell
-32,761
Closed -$1.23M – 1330
2017
Q3 		$1.23M Sell
32,761
-29,500
-47% -$960K ﹤0.01% 984
2017
Q2 		$1.74M Sell
62,261
-23,400
-27% -$697K ﹤0.01% 909
2017
Q1 		$2.94M Sell
85,661
-28,726
-25% -$1.01M ﹤0.01% 810
2016
Q4 		$3.3M Sell
114,387
-27,300
-19% -$722K 0.01% 763
2016
Q3 		$4.51M Sell
141,687
-9,313
-6% -$316K 0.01% 725
2016
Q2 		$4.9M Sell
151,000
-26,400
-15% -$883K 0.01% 681
2016
Q1 		$4.96M Buy
177,400
+46,900
+36% +$1.02M 0.01% 677
2015
Q4 		$4.65M Sell
130,500
-4,400
-3% -$155K 0.01% 679
2015
Q3 		$4.46M Buy
134,900
+6,000
+5% +$250K 0.01% 661
2015
Q2 		$5.4M Sell
128,900
-2,900
-2% -$112K 0.01% 645
2015
Q1 		$4.29M Buy
131,800
+13,700
+12% +$471K 0.01% 699
2014
Q4 		$3.75M Buy
118,100
+3,000
+3% +$85.1K 0.01% 735
2014
Q3 		$2.85M Buy
115,100
+8,000
+7% +$187K ﹤0.01% 767
2014
Q2 		$2.42M Buy
107,100
+65,900
+160% +$1.38M ﹤0.01% 803
2014
Q1 		$1M Buy
41,200
+3,300
+9% +$83.5K ﹤0.01% 905
2013
Q4 		$947K Buy
37,900
+5,200
+16% +$123K ﹤0.01% 890
2013
Q3 		$898K Buy
32,700
+3,800
+13% +$79.4K ﹤0.01% 885
2013
Q2 		$525K Buy
+28,900
New +$398K ﹤0.01% 925

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TD Asset Management's ACAD Position: Q4 2025 in Review

TD Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 65,000 shares — an estimated $1.39M sold.

TD Asset Management first reported a position in ACAD in Q2 2013 and held it in 44 quarters. The position peaked at $12.4M in Q2 2020. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • TD Asset Management reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • TD Asset Management sold 65,000 Acadia Pharmaceuticals shares in Q4 2025, an estimated $1.39M.
  • TD Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 44 quarters.
  • TD Asset Management's Acadia Pharmaceuticals position peaked at $12.4M in Q2 2020.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on TD Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.